Zusammenfassung
Hintergrund
Die Aggregation des mikrotubuliassoziierten Proteins Tau in Nervenzellen definiert eine Gruppe neurodegenerativer Krankheiten, welche Tauopathien genannt werden.
Ziel der Arbeit
Erstellung eines aktuellen Übersichtsartikels zum Stand der klinischen Forschung auf dem Gebiet der Tauopathien.
Material und Methoden
Systematischer Review über die Literatur der letzten 10 Jahre.
Ergebnis
Tau wird vermehrt als hochvariables Protein wahrgenommen, welches ein Spektrum von Erkrankungen molekular definiert. Das klinische Bild der Tauopathien reicht von Demenzen bis zu hypokinetischen Bewegungsstörungen. Genetische Variation am Tau-Lokus kann Krankheiten auslösen oder das Krankheitsrisiko verändern. Modifikationen im Tau-Protein können Nervenzellen schädigen und die Krankheitsprozesse durch das Gehirn propagieren. Daher kann Tau sowohl als serologischer als auch als bildgebender Biomarker verwendet werden. Tau bietet auch ein breites Spektrum an rationalen therapeutischen Interventionsmöglichkeiten, um die Krankheitsprogression zu modifizieren. Diese Erkenntnisse haben zu modernen klinischen Prüfungen geführt.
Diskussion
Das Feld der Tauopathien ist in raschem und dynamischem Fortschritt begriffen, der eine intensive interdisziplinäre Kooperation voraussetzt.
Abstract
Background
The microtubule-associated tau protein is the defining denominator of a group of neurodegenerative diseases termed tauopathies.
Objective
Provide a timely state of the art review on recent scientific advances in the field of tauopathies.
Material and methods
Systematic review of the literature from the past 10 years.
Results
Tau proteins are increasingly being recognized as a highly variable protein, underlying and defining a spectrum of molecularly defined diseases, with a clinical spectrum ranging from dementia to hypokinetic movement disorders. Genetic variation at the tau locus can trigger disease or modify disease risk. Tau protein alterations can damage nerve cells and propagate pathologies through the brain. Thus, tau proteins may serve both as a serological and imaging biomarker. Tau proteins also provide a broad spectrum of rational therapeutic interventions to prevent disease progression. This knowledge has led to modern clinical trials.
Conclusion
The field of tauopathies is in a state of dynamic and rapid progress, requiring close interdisciplinary collaboration.
Literatur
Kovacs GG (2015) Neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol 41:3–23
Ahmed Z, Bigio EH, Budka H et al (2013) Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol 126:537–544
Crary JF, Trojanowski JQ, Schneider JA et al (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128:755–766
Kovacs GG, Ferrer I, Grinberg LT et al (2016) Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol 131:87–102
McKee AC, Stein TD, Kiernan PT, Alvarez VE (2015) The neuropathology of chronic traumatic encephalopathy. Brain Pathol 25:350–364
Gelpi E, Höftberger R, Graus F et al (2016) Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 132:531–543
Irwin DJ (2016) Tauopathies as clinicopathological entities. Parkinsonism Relat Disord 22:29–33
Kouri N, Whitwell JL, Josephs KA et al (2011) Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 7:263–272
Josephs KA, Petersen RC, Knopman DS et al (2006) Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 10:41–48
Graff-Radford J, Josephs KA, Parisi JE et al (2016) Globular glial tau pathology presenting as semantic variant primary progressive aphasia. JAMA Neurol 73:123–125
Respondek G, Kurz C, Arzberger T et al (2017) Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 32:995–1005
Chahine LM, Reibeiz T, Reibeiz JJ (2014) Corticobasal syndrome: five new things. Neurol Clin Pract 4:304–312
van Eimeren T, Bischof GN, Drzezga AE (2017) Is tau imaging more than just ‘upside-down’ FDG imaging? J Nucl Med 117:190082
Hammes J, Bischof GN, Giehl K et al (2017) Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy. Mov Disord 32:170–171
Schweyer K, Busche MA, Hammes J et al (2018) Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy. Neurology 90:482–485
Mattsson N, Lönneborg A, Boccardi M et al (2017) Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5‑phase development framework. Neurobiol Aging 52:196–213
Hu WT, Watts K, Grossman M et al (2013) Reduced CSF p‑Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology 81:1945–1952
Boxer AL, Yu JT, Golbe LI et al (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16:552–563
Rojas JC, Bang J, Lobach IV et al (2018) CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 90:e273–e281
Pickering-Brown S, Baker M, Yen S‑H et al (2000) Pick’s disease is associated with mutations in the tau gene. Ann Neurol 48:859–867
Forrest SL, Kril JJ, Stevens CH et al (2018) Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain 141:521–534
Donker Kaat L, Boon AJ, Azmani A et al (2009) Familial aggregation of parkinsonismin in progressive supranuclear palsy. Neurology 73:98–105
Kouri N, Carlomagno Y, Baker M et al (2014) Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration. Acta Neuropathol 127:271–282
Höglinger GU, Melhem NM, Dickson DW et al (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43:699–705
Kouri N, Ross OA, Dombroski B et al (2015) Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun 6:7247
Iqbal K, Liu F, Gong CX (2016) Tau and neurodegenerative disease: the story so far. Nat Rev Neurol 12:15–27
Clinicaltrials.gov (2018) ncbi.nlm.nih.gov/pubmed. Zugegriffen: 05.01.2018
Alzforum (2018) https://www.alzforum.org/. Zugegriffen: 05.01.2018
Stamelou M, Reuss A, Pilatus U et al (2008) Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 23:942–949
Apetauerova D, Scala SA, Hamill R et al (2016) CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm 3:e266
Tolosa E, Litvan I, Hoglinger GU et al (2014) A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 29:470–478
Hoglinger GU, Huppertz HJ, Wagenpfeil S et al (2014) Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord 29:479–487
Leclair-Visonneau L, Rouaud T, Debilly B et al (2016) Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin Neurol Neurosurg 146:35–39
Boxer AL, Lang AE, Grossman M et al (2014) Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 13:676–685
Boxer AL, Qureshi I, Grundman M et al (2018) Multiple ascending dose study of the tau-directed monoclonal antibody BIIB092 in patients with progressive supranuclear palsy. Neurology 90(15 Supplement):S27.004
Novak P, Schmidt R, Kontsekova E et al (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 16:123–134
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
G. G. Kovacs, G. Respondek hielt Vorträge für GE Health. G. U. Höglinger wurde gefördert von Neuropore, GE Health; beriet AbbVie, Alzprotect, Asceneuron, Axon Neuroscience, Biogen, Bristol-Myers Squibb, Novartis, Roche, UCB; hielt Vorträge für AbbVie, Roche, Teva, UCB. T. vanEimeren, E. Höller, J. Levin, U. Müller, S. Schwarz, T. W. Rösler und K. Schweyer geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Kovacs, G.G., Respondek, G., van Eimeren, T. et al. Tauopathien. Nervenarzt 89, 1083–1094 (2018). https://doi.org/10.1007/s00115-018-0584-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00115-018-0584-3
Schlüsselwörter
- Mikrotubuliassoziiertes Tau-Protein
- Progressive supranukleäre Parese
- Kortikobasale Degeneration
- Biomarker
- Kausale Therapie